Eicosapentaenoic Acid Blocks Cyclosporine A-Induced Pancreatic Dysfunction but not Immunosuppression

Takashi Majima¹*, Kazuki Sasaki², Hiroshi Ohara², Norio Takahashi²

¹Department of Pharmacy Practice and Pharmaceutical Sciences, Setsunan University, Hirakata, Osaka, Japan.
²Department of Clinical Pharmacy, School of Pharmaceutical Sciences, Ohu University, Koriyama, Fukushima, Japan.

ABSTRACT
Cyclosporine A (CsA) is a widely used immunosuppressant in transplantation medicine. However, it has oxidative stress-induced side effects, including nephrotoxicity, hypertension, dyslipidemia, and glucose intolerance; particularly, post-transplant diabetes mellitus, accompanied by alterations of pancreatic islet cells, has been reported as a major adverse event. Recent research indicates that omega-3 polynsaturated fatty acids, such as eicosapentaenoic acid (EPA), have antioxidant and anti-inflammatory activities. However, protective effects of EPA against CsA-induced alterations of pancreatic islet cells and hyperglycemia have not been examined in long-term administration of CsA in rats. The aim of this study was to determine whether EPA can abrogate these negative effects by assessing pancreatic islet cell dysfunction, vacuolation, and hyperglycemia in rats continuously treated with CsA. These pathologies were significantly improved by concomitant administration of EPA. Importantly, EPA did not affect the immunosuppressive effects of CsA, as evidenced by nuclear translocation of nuclear factor of activated T-cells in pancreatic tissue in response to lipopolysaccharide stimulation. Thus, EPA can be used to prevent CsA-induced oxidative stress and/or inflammation in pancreatic islets. Our data also suggest that EPA can be used in conjunction with CsA to mitigate its harmful side effects while preserving its immunosuppressant properties in transplant patients.

INTRODUCTION
Cyclosporine A (CsA) is widely used in transplantation medicine as an immunosuppressant. This effect is exerted via inhibition of cytokine production [e.g., interleukin (IL)-2] by helper T cells. However, long-term use of CsA has adverse effects such as nephrotoxicity, hypertension, dyslipidemia, and glucose intolerance (Heisel et al., 2004; Penformis and Kury-Paulin, 2006; Lim et al., 2012; Piao SG et al., 2012). CsA-induced oxidative stress has been found to play a critical role in pancreatic islet dysfunction, including hyperglycemia, reduced insulin levels and islet mass, and increased apoptotic cell death and macrophage infiltration (Gómez et al., 2004; Lim et al., 2013). Post-transplant diabetes mellitus (PTDM) is a major adverse event in 10 – 25% of patients receiving immuno-suppressive therapy (Drachenberg et al., 1999; Jiang et al., 1999; Gómez et al., 2004; Lim et al., 2013), which can lead to reduced graft survival and increased risk of infectious and cardiovascular diseases. The pathogenesis of PTDM is thought to involve direct toxicity of CsA to pancreatic beta cells and a consequent reduction in insulin synthesis and secretion (Yang et al., 2002; Gómez et al., 2004). Recent studies have shown that chronic CsA administration impairs glucose tolerance and induces nephrotoxicity, which is characterized by striped tubulointerstitial fibrosis, tubular atrophy, and hyalinosis of afferent arterioles, resulting from oxidative stress and inflammation (Hahn et al., 1986, 1992; Düfer et al., 2001; Yang et al., 2002; Justo et al., 2003; Chung et al., 2005; Song et al., 2009; Lim SW et al., 2012; Piao et al., 2012). The search for drugs that can ameliorate CsA-induced adverse side effects related to glucose intolerance is on-going. Omega-3 polynsaturated fatty acids (PUFAs), including eicosapentaenoic acid (EPA), have antioxidant properties and anti-inflammatory activity, and thus have beneficial effects on cardiovascular health (Shimojo et al., 2006; Weylandt et al., 2008; Oh et al., 2010).
We hypothesized that EPA could reduce glucose intolerance and thereby prevent organ injury caused by CsA. The aim of this study was to test this hypothesis using a rat model of chronic CsA treatment. We found that co-administration of EPA suppressed the CsA-induced increases in plasma glucose concentration and pancreatic islet cell alterations.

MATERIAL AND METHODS

Reagents

Rabbit polyclonal anti-nuclear factor of activated T-cells 3 (NFATc3) (Santa Cruz Biotechnology, Dallas, TX, USA) and rabbit monoclonal anti-β-actin (13E5) (Cell Signaling Technology, Danvers, MA, USA) antibodies were used in the experiments. TO-PRO-3 and Alexa 488-conjugated rabbit IgG were purchased from Life Technologies (Carlsbad, CA, USA). CsA was obtained from LC Laboratories (Boston, MA, USA), and EPA was from Nuchek Prep (Elysian, MN, USA).

Animal groups and treatments

Wistar/ST rats (6-week-old) were purchased from Nihon SLC (Shizuoka, Japan). Rats were housed in a controlled environment under a 12:12-h light/dark cycle with the temperature maintained at 25 °C, and had free access to standard chow and water. Rats were divided into three groups (3-5 rats per group): control, CsA, and CsA + EPA. Control rats received vehicle treatment (saline followed by olive oil), those in the CsA group were treated daily with 40 mg/kg CsA in olive oil via gavage, and those in the CsA + EPA group were treated daily with 15 mg/kg EPA in saline followed by 40 mg/kg CsA in olive oil via gavage. Animals were euthanized at the end of the 2-week treatment period.

Intraperitoneal glucose tolerance test (IPGTT)

The IPGTT was performed on day 15. Briefly, after 1 day of fasting, rats were injected with 20% d-glucose solution (2 g/kg), with blood glucose concentration measured immediately before and 15, 30, 60, 90, 120, and 180 min after injection, using a glucose analyzer (Glutest Neo Super; Sanwa Kagaku Kenkyusho, Nagoya, Japan). The area under the curve of glucose (AUCg) was calculated by trapezoidal estimation from values obtained in the IPGTT.

Histological analysis

After IPGTT, rats were anesthetized by low-dose diethyl ether inhalation, followed by intraperitoneal injection of pentobarbital (30 mg/kg, Virbac, Carros, France). The pancreas was dissected and the rats were euthanized by cervical dislocation. Then, the pancreas was immersed in 4% paraformaldehyde in phosphate-buffered saline (PBS), followed by overnight incubation in 30% sucrose solution. Paraaffin-embedded pancreas tissue was serially sectioned at a thickness of 4 µm on a microtome (Leica Microsystems, Wetzlar, Germany), followed by hematoxylin and eosin (H&E) staining.

Immunofluorescence microscopy

To investigate whether EPA alters the immunosuppressive effect of CsA, rats were intraperitoneally injected with saline with or without 1.0 mg/kg lipopolysaccharide (LPS). Rats were euthanized 2 h later and the pancreas was dissected and fixed in 4% paraformaldehyde for 24 h, then immersed in 30% sucrose for 48 h at 4°C. After embedding in OCT compound (Sakura Finetek, Tokyo, Japan), samples were frozen in liquid nitrogen and stored at −80°C. The paraaffin-embedded tissue was serially cut into 30-µm-thick sections on a cryostat (Leica Microsystems).

The sections were permeabilized with 0.5% Triton™ X-100 for 10 min and then blocked with 10% goat serum (Sigma-Aldrich, St. Louis, MO, USA) in PBS, followed by antigen retrieval using Histo VT One (Nacalai Tesque, Kyoto, Japan). NFATc3 and nuclei were labeled with anti-NFATc3 antibody and TO-PRO-3, respectively. Five randomly selected sections per rat were imaged by confocal microscopy. Vacuolated pancreatic tissues were defined for each section. Samples were visualized with an LSM510 confocal microscope (Zeiss, Oberkochen, Germany).

Statistical analysis

Statistical analyses were performed using GraphPad Prism v.5.01 software (GraphPad Software Inc., La Jolla, CA, USA). Data were analyzed via one-way analysis of variance and multiple comparisons between treatment groups were made with the Dunnett's multiple comparison test or Bonferroni post hoc test. Results are presented as mean ± SEM. A P value ≤ 0.05 was considered statistically significant.

RESULTS AND DISCUSSION

EPA reverses the decrease in glucose tolerance induced by CsA

The effects of CsA and CsA + EPA administration for 2 weeks were evaluated by IPGTT. Consistent with a previous report (Lim et al., 2013), blood glucose level increased in the CsA group compared with that of untreated controls at each time point (n = 5, Dunnett’s multiple range test) (Fig.1A). However, this increase was abrogated by co-administration of EPA.

These trends were confirmed by AUCg as an indicator of decreased glucose tolerance (n = 5, Dunnett’s multiple comparison test) (Fig. 1B).

EPA abrogates pancreatic islet vacuolization caused by CsA

We examined whether long-term administration of CsA could damage pancreatic islet tissue by H&E staining (Fig. 2). CsA treatment for 2 weeks induced the formation of vacuoles in pancreas islets relative to untreated control rats. However, the number of vacuoles per islet was significantly reduced by co-administration of EPA compared with that observed with CsA alone, recovering almost to the level of the control group (control vs. CsA; P < 0.001, control vs. CsA + EPA; not significant. n = 3, Dunnett’s Multiple range test).
EPA does not alter the immunosuppressive effects of CsA
Nfatc3 is a transcription factor that regulates the expression of cytokines such as LPS-induced IL-2, and thereby plays an important role in the immune response. Treatment with CsA inhibited LPS-induced nuclear translocation of NFATc3 in the absence or presence of EPA (n = 3, Bonferroni post-hoc test) (Fig. 3B). These results suggest that EPA does not alter the ability of CsA to inhibit NFATc3 nuclear translocation, and, hence, does not impede immunosuppression by CsA. Although several studies have shown that omega-3 PUFAs have antioxidant and anti-inflammatory effects (Gómez et al., 2004; Weylandt et al., 2008), the present work demonstrates for the first time that EPA treatment reverses damage to pancreatic islet cells caused by long-term administration of CsA in rats. Blood glucose levels increased 30 min after injection of glucose and returned to the baseline value after 180 min in all rats. However, CsA administration resulted in a persistent increase in blood glucose level at 15, 30, and 60 min relative to controls, which was suppressed by co-administration of EPA. This was confirmed by calculating AUCg 180 min after glucose administration and is consistent with previous reports that immunosuppressant-induced pancreatic dysfunction leads to hyperglycemia (Hahn et al., 1986, 1992; Piao et al., 2012). We also demonstrated that long-term administration of CsA induced vacuole formation, which was abrogated by EPA. This is in accordance with a report that oxidative stress or free radicals arising from chronic administration of immunosuppressants, such as CsA, caused pancreatic tissue dysfunction in a transplant patient (Lim et al., 2013). Based on these findings, we propose that elevation of blood glucose level upon long-term CsA administration is the result of pancreatic islet perforation, degeneration of pancreatic tissue, and consequent impairment in insulin secretion, and that EPA protects pancreatic tissue against these effects. Our immunofluorescence analysis revealed that nuclear translocation of NFATc3 in pancreatic cells induced by LPS was blocked by CsA in the absence or presence of EPA, indicating that EPA does not affect the immunosuppressive activity of CsA and that CsA-induced immunosuppression and pancreatic tissue damage are mediated via distinct mechanisms. CsA causes oxidative stress in the pancreas, leading to inflammation of islets. It was previously demonstrated that the antioxidant vitamins C and E could improve pancreatic disorder (Gómez et al., 2004). In addition to its antioxidant properties, EPA also suppresses inflammation and subsequent fibrosis (Weylandt et al., 2008; Oh et al., 2010). It was previously reported that n-3 PUFAs, such as docosahexaenoic acid, more efficiently inhibited protein degradation than EPA by regulating inhibitor of κBα (IκBα)/nuclear factor-κB (NF-κB) signaling via activation of peroxisome proliferator-activated receptor-γ gene expression (Wang et al., 2013); moreover, NF-κB activation in pancreatic acinar cells has been shown to exacerbate pancreatitis (Huang et al., 2013). Thus, EPA may suppress CsA-induced NF-κB activation by modulating IκBα/NF-κB signaling.
Fig. 3: Effect of EPA on immunosuppression by CsA. NFATc3 accumulation in pancreatic islet cell nuclei in rats treated with vehicle, CsA, or CsA + EPA. Scale bars, 50 µm. (A) yellow nuclei are cells that are double positive for NFATc3 (i.e., NFAT – positive nuclei). (B) Quantitative analysis of the number of NFATc3 – positive nuclei in specific areas of pancreatic islets. **P < 0.01, vehicle vs. LPS; *P < 0.05, LPS vs. LPS + CsA; *P < 0.05, LPS vs LPS + CsA + EPA (n = 3 per group). Error bars indicate mean ± SEM of three independent experiments. Abbreviations: CsA, cyclosporine A; EPA, eicosapentaenoic acid; NFATc3, nuclear factor of activated T-cells 3.

CONCLUSION

In conclusion, our results indicate that EPA administration can prevent the adverse effects associated with CsA without affecting its immunosuppressive function in transplant patients.

ACKNOWLEDGEMENT

The authors thank K. Seki for providing expertise on immunohistochemical techniques and for helpful discussions, and the referees for useful comments.

ETHICAL APPROVALS

Animal Rights

The animal protocols used in this study were in accordance with the animal care guidelines of each institution and were approved by the local ethical committee (The Ohu University Medical School Animal Care and Use Committee, 2012-59, and 2013-29).

Financial support and sponsorship: Nil.

Conflict of Interests: There are no conflicts of interest.

REFERENCES


How to cite this article: